Pembrolizumab plus OT-101 for pleural mesothelioma after failed immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests OT-101 given with pembrolizumab (an immunotherapy) in people with malignant pleural mesothelioma whose cancer worsened after prior checkpoint inhibitor treatment. It may help shrink tumors or control the disease after standard immunotherapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have malignant pleural mesothelioma proven by pathology (biopsy).
- Your cancer must have grown after prior immune therapy (anti–PD-1, anti–PD-L1, or anti–CTLA-4), as judged by your doctor.
- You are age 18 or older and can do daily activities fairly well (ECOG 0 to 1).
- You have measurable disease on the study scan, and you can provide a tumor biopsy before starting treatment (new or stored/archival).
- Your body is strong enough for treatment based on recent lab/organ checks done within about 10 days of starting.
- If you are pregnant, breastfeeding, or plan to become pregnant/father a child during the study period (and after), you cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests a new drug (BMS-986504) combined with standard chemotherapy or immunotherapy for three types of advanced solid tumors: mesothelioma, gastroesophageal cancer, or bladder cancer. It may be an option if your tumor has a specific genetic change called MTAP deletion.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy for people with malignant mesothelioma that cannot be treated with surgery or radiation. It may be an option whether you are starting treatment for the first time or have had up to three prior treatments.
This study tests whether atezolizumab given after surgery and chemotherapy can lower the risk of mesothelioma coming back compared with a placebo. It may help by boosting the immune system to control remaining microscopic cancer cells.
Hear when a new Malignant Pleural Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.